



PAT A. CERUNDOLO

PARTNER

Boston

☎ 617.832.1252

✉ pcerundolo@foleyhoag.com

I advise biopharmaceutical drug manufacturers regarding state policies, laws and regulations that implicate access in the commercial and Medicaid markets.

Pat Cerundolo has an extensive background representing biopharmaceutical clients and industry trade associations in a wide range of state legislative and regulatory initiatives, including drug product access in the public and private payor environment, drug price transparency laws, physician marketing laws, and value based arrangements.

Pat has a deep understanding of a broad range of state-level laws and policies that impact biopharmaceutical manufacturers, including drug coverage and reimbursement, state efforts at drug price controls and transparency, Medicaid access, value based arrangements, and associated state laws and regulations. He has extensive experience in complex legislative and regulatory drafting related to these topics, and has particular expertise in managing multi-state legislative and regulatory advocacy initiatives focused on these and other topics on behalf of biopharmaceutical manufacturing clients. His knowledge of the intricacies of state-level policymaking reflects three years of experience in the Office of the General Counsel at the Commonwealth of Massachusetts Executive Office for Administration and Finance, where he focused on a range of legislative initiatives as well as general regulatory matters overseen by that agency.

RELATED INDUSTRIES

[Life Sciences >](#)

[Technology >](#)

[Healthcare >](#)

RELATED PRACTICES

[Federal Government Strategies >](#)

[Life Sciences Coverage & Payment >](#)

[State Legislative & Regulatory Policy For Life Sciences Companies >](#)

EDUCATION

- Boston College Law School, J.D., 1998
- Harvard College, A.B., 1992

BAR AND COURT ADMISSIONS

BAR ADMISSIONS

- Massachusetts

HONORS & INVOLVEMENT

INVOLVEMENT

- Massachusetts Association for Mental Health (MAMH), Board Member

SPEAKING ENGAGEMENTS

- "New Developments in Drug Pricing and Reimbursement," Boston Bar Association Life Sciences Conference (September 2018)
- "Discussion on Advances in Biosimilars to US and EU Policies on the Use of Biosimilars," EU-US eHealth Marketplace and Conference (October 2014)
- "Understanding the New U.S. Sunshine Act and Its Impact on Health Care Providers and Industry," Lex Mundi Webinar (January 2012)
- "The Massachusetts Lobbying and Ethics Law: The View 6 Months Later," MCLE (June 2010)
- "LAW & POLICY: Massachusetts' New Lobbying Laws: A Primer," MassBio (March 2010)
- "Who Me, a Lobbyist? How Board Volunteers, Business Owners, and Consultants May Now Be Considered Lobbyists in Massachusetts," NAIOP Massachusetts (January 2010)
- "Dr. Disclosure: What the Massachusetts Pharmaceutical and Medical Device Marketing Laws Mean for You," Crimson Life Sciences Webinar (July 2009)
- "Are You Ready to Comply with Massachusetts' New Pharmaceutical and Medical Device Code of Conduct Law?," MassMEDIC (January 2009)
- "Understanding the Proposed Massachusetts Pharmaceutical Marketing Regulations," Massachusetts Biotechnology Council (January 2009)

